Skip to content
VD

Venmax Drugs & Pharmaceuticals

531015 BSE
Price unavailable

Venmax Drugs & Pharmaceuticals (VENMAX) share price was ₹13.06 at the 28 Oct 2026 close; market capitalisation ₹18.91 Cr; P/E (TTM) 52.24; sector Healthcare. The share price fell 51.5% over the year to 28 Oct 2026 (adjusted for splits and bonuses). In the Jun 2026 quarter, revenue was ₹2.48 Cr, against ₹1.21 Cr a year earlier and net profit was ₹0.12 Cr, against ₹0.04 Cr a year earlier (compared with Jun 2025). Promoters held 10.46% of Venmax Drugs & Pharmaceuticals in Sep 2026, unchanged from Jun 2026. Its Tapetide Score is 38/100 (Weak) as of 28 Oct 2026.

Close 28 Oct 2026 ₹13.06 −13.01 −49.90% 1Y

Key Fundamentals

MicrocapPharmaceuticals & BiotechnologyHealthcare
Market Cap
₹18.91 Cr
P/E (TTM)
52.24
EBITDA
₹30.00 L
Return on Equity
1.76%
Debt to Equity
0.02
Book Value
₹14.37
EPS (TTM)
₹0.25
52W High
₹31.49
52W Low
₹12.71

Price-based figures as of 28 Oct 2026, 15:30 IST · EPS basis: Standalone · TTM

Peer Comparison

Healthcare › Pharmaceuticals

Sun Pharma
₹1,766.1035.034,23,747 Cr5.070.91%13.79%17.94%61,848 Cr12,117 Cr
Divis Laboratories
₹9,626.0087.372,55,540 Cr15.250.32%15.32%18.96%11,682 Cr2,925 Cr
Torrent Pharmaceuticals
₹4,595.7072.151,74,806 Cr9.510.82%12.16%9.06%17,058 Cr2,156 Cr
Laurus Labs
₹2,183.70107.891,17,988 Cr22.260.09%16.38%19.67%7,323 Cr1,090 Cr
Zydus Life Science
₹1,180.4026.271,17,745 Cr4.340.09%16.99%19.24%28,515 Cr4,593 Cr
Dr Reddys Laboratories
₹1,340.7034.721,11,906 Cr2.880.61%10.87%13.94%34,247 Cr3,184 Cr
Cipla
₹1,370.7032.841,10,733 Cr3.130.96%11.21%14.88%28,589 Cr3,356 Cr
Venmax Drugs & Pharmaceuticals (this company)
—52.2419 Cr0.910.00%1.76%1.96%9 Cr0 Cr
Median 8 companies₹1,766.1043.641,17,867 Cr4.710.47%12.98%16.41%22,787 Cr3,055 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the live price; other metrics are as reported in filings. A dash means the figure is not published for that company.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

38 Weak
Overall score

Data confidence 95/100

Category scores

Quality Poor 21
Returns, margins, earnings quality 22% weight
Valuation Poor 24
Cheap vs sector & own history 24% weight
Growth Strong 99
Sales & profit trajectory 9% weight
Financial Health Strong 83
Solvency, leverage, coverage 9% weight
Momentum Poor 5
Trend strength, vol-adjusted 12% weight
Ownership Average 50
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

3
  • Company is almost debt free.
  • Stock is trading at 1.12 times its book value
  • Debtor days have improved from 247 to 65.1 days.

Weaknesses

2
  • Promoter holding has decreased over last quarter: -3.34%
  • Promoter holding is low: 10.5%

Technical Indicators

Oscillators

Neutral

Bearish
2
Neutral
5
Bullish
2

Overall

Bearish

Bearish
12
Neutral
5
Bullish
2

Moving Averages

Bearish

Bearish
10
Neutral
0
Bullish
0

Growth Rate

Revenue Growth
332% higher than 3Y

change over 1 year

Net Income Growth
—

Cash Flow Change
-380%

change over 1 year

EBITDA Margin Change
-937%

change over 1 year Operating margin 4.84% · Jun 2026

Quarterly Results

Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
0
0
0
0
0.1
0.17
0.2
0.33
1.21
1.32
1.55
3.94
2.48
Expenses
0.03
0.03
0.01
0.04
0.12
0.47
0.69
0.57
1.17
1.27
1.58
3.92
2.36
Operating Profit
-0.03
-0.03
-0.01
-0.04
-0.02
-0.3
-0.49
-0.24
0.04
0.05
-0.03
0.02
0.12
OPM %
—
—
—
—
-20%
-176.47%
-245%
-72.73%
3.31%
3.79%
-1.94%
0.51%
4.84%
Other Income
0.05
0
0.05
0.1
0.03
0
0
1.02
0
0
0.07
0.09
0
Interest
0
0
0
0
0
0
0
0
0
0
0
0
0
Depreciation
0
0
0
0
0
0
0
0
0
0
0
0
0
PBT
0.02
-0.03
0.04
0.06
0.01
-0.3
-0.49
0.78
0.04
0.05
0.04
0.11
0.12
Tax %
0%
0%
25%
16.67%
0%
0%
0%
0%
0%
40%
25%
0%
0%
Net Profit
0.02
-0.03
0.03
0.05
0.01
-0.3
-0.5
0.78
0.04
0.02
0.03
0.11
0.12
EPS (₹)
0.04
-0.06
0.06
0.1
0.02
-0.57
-0.95
1.49
0.08
0.02
0.04
0.09
0.1
Figures in ₹ Crores

Profit & Loss

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
2.43
1.93
0.26
0
0.15
0.47
0.17
0
0
0
0.81
8.02
9.29
Expenses
2.54
2.07
0.88
0.23
0.38
0.72
0.5
0.12
0.19
0.11
1.87
7.9
9.13
Operating Profit
-0.11
-0.14
-0.62
-0.23
-0.23
-0.25
-0.33
-0.12
-0.19
-0.11
-1.06
0.12
0.16
OPM %
-4.53%
-7.25%
-238.46%
—
-153.33%
-53.19%
-194.12%
—
—
—
-130.86%
1.5%
1.72%
Other Income
0
0
-0.72
0
0
0
0.18
1.98
0.42
0.2
1.05
0.16
0.16
Interest
0
0
0
0.01
0
0
0
0
0
0
0
0
0
Depreciation
0
0
0
0
0.01
0.01
0.01
0.01
0.01
0.01
0.01
0
0
PBT
-0.11
-0.14
-1.34
-0.24
-0.24
-0.26
-0.16
1.85
0.22
0.08
-0.02
0.28
0.32
Tax %
-36.36%
0%
0%
0%
0%
3.85%
0%
0%
0%
25%
0%
10.71%
—
Net Profit
-0.08
-0.14
-1.34
-0.24
-0.24
-0.27
-0.16
1.85
0.23
0.06
-0.01
0.25
0.28
EPS (₹)
-0.15
-0.27
-2.56
-0.46
-0.46
-0.52
-0.31
3.53
0.44
0.11
-0.02
0.22
0.25
Div. Payout %
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
—
Figures in ₹ Crores

Balance Sheet

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
5.24
5.24
5.24
5.24
5.24
5.24
5.24
5.24
5.24
5.24
5.24
11.58
Reserves
-4.9
-5.04
-7.11
-7.35
-7.59
-7.86
-8.03
-6.18
-5.95
-5.89
-0.83
2.53
Borrowings
1.5
1.72
1.85
2.04
2.24
2.52
2.33
0.35
0.35
0.35
0.05
0.33
Other Liabilities
1.85
0.68
0.16
0.14
0.44
0.56
0.76
0.8
0.57
0.38
0.71
1.76
Total Liabilities
3.69
2.6
0.14
0.07
0.33
0.46
0.3
0.21
0.21
0.08
5.17
16.2
Fixed Assets
0
0
0
0
0.11
0.1
0.09
0.08
0.07
0.07
0.04
0.04
CWIP
0
0
0
0
0
0
0
0
0
0
0
0
Investments
0.01
0.01
0
0
0
0
0
0
0
0
0
0
Other Assets
3.68
2.59
0.14
0.07
0.22
0.36
0.21
0.13
0.14
0.01
5.13
16.16
Total Assets
3.69
2.6
0.14
0.07
0.33
0.46
0.3
0.21
0.21
0.08
5.17
16.2
Figures in ₹ Crores

Cash Flow

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
-0.1
-0.19
-1.06
-0.26
-0.05
-0.28
0.26
1.91
0
0
-2.29
-11
Investing
0
0
0.01
0
-0.11
0
0
0
0
0
0
0
Financing
0.1
0.22
1.02
0.26
0.16
0.28
-0.19
-1.98
0
0
4.77
9.74
Net Cash Flow
0
0.03
-0.03
0
0
0
0.07
-0.07
0
0
2.48
-1.26
Free Cash Flow
-0.1
-0.19
-1.05
-0.26
-0.17
-0.28
0.26
1.91
0
0
-2.29
-11
CFO/OP
127
136
171
113
22
112
-79
-1,592
0
-18
216
-9,142
Figures in ₹ Crores

Ratios

Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
21.03
129
0
—
0
31.06
85.88
—
—
—
428
65.08
Inventory Days
225
0
0
—
446
251
0
—
—
—
27.72
50.14
Days Payable
252
—
—
—
1,257
456
—
—
—
—
291
84.23
Cash Conversion Cycle
-5.04
129
0
—
-811
-174
85.88
—
—
—
165
30.99
Working Capital Days
-3
5.67
-2,723
—
-5,986
-2,112
-6,334
—
—
—
874
588
ROCE %
-6.01%
-7.45%
-52.63%
—
—
—
—
—
—
—
-0.96%
2.96%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Venmax Drugs & Pharmaceuticals insights

61 extracted metrics + investor summaries across FY09–FY27.

Shareholding Pattern

Public75.66%Promot.10.46%Others13.87%As ofSep 2026

Documents

Frequently Asked Questions about Venmax Drugs & Pharmaceuticals

What does Venmax Drugs & Pharmaceuticals Ltd do?
Incorporated in 1998, Venmax Drugs & Pharmaceuticals Ltd is engaged in the business of IT & ITES services[1]
Where is Venmax Drugs & Pharmaceuticals Ltd (VENMAX) listed?
Venmax Drugs & Pharmaceuticals Ltd trades under code 531015 on the BSE.
Which sector does Venmax Drugs & Pharmaceuticals Ltd belong to?
Venmax Drugs & Pharmaceuticals Ltd is classified under the Healthcare sector, in the Pharmaceuticals industry.
What is the market capitalisation of Venmax Drugs & Pharmaceuticals Ltd?
Venmax Drugs & Pharmaceuticals Ltd has a market capitalisation of ₹18.91 Cr as of 28 Oct 2026, which places it in the Small Cap band.
What is the PE ratio of Venmax Drugs & Pharmaceuticals Ltd?
Venmax Drugs & Pharmaceuticals Ltd trades at a PE ratio of 52.24 as of 28 Oct 2026, on earnings per share of ₹0.25, against a book value of ₹14.37 per share.
What is the 52-week high and low of Venmax Drugs & Pharmaceuticals Ltd?
Over the last 52 weeks Venmax Drugs & Pharmaceuticals Ltd has traded between ₹12.71 and ₹31.49 as of 28 Oct 2026.
What is the Return on Equity (ROE) of Venmax Drugs & Pharmaceuticals Ltd?
Venmax Drugs & Pharmaceuticals Ltd reported a return on equity of 1.76%. Its debt-to-equity ratio is 0.02.

Company Information

Incorporated in 1998, Venmax Drugs & Pharmaceuticals Ltd is engaged in the business of IT & ITES services[1]

Website venmaxdrugs.com
Face Value ₹ 10
Shares Outstanding 1,44,75,524

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/531015.md for Venmax Drugs & Pharmaceuticals Ltd: company profile, latest price, key fundamentals, the Tapetide Score, growth rates, quarterly and annual financial statements, shareholding pattern, technical indicators, analyst ratings and exchange filings.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Pharma stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month